RxDoctor Payments Data

Chandresh Shah, MD

Internal Medicine · Austell, GANPI 1770655987

Payments from drug & device makers

$4,030in general payments, 2019–2025

Across 152 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$989
  • AstraZeneca$832
  • AbbVie$438
  • Johnson & Johnson$356
  • Pfizer$227
  • Amgen$198
  • plus $989 from 18 others

What the payments were for

  • Consulting fees$80020%
  • Food & beverage$3,23080%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,030 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$47,057
Medicare patients
86
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Soliqua 100-33Insulin Glargine/Lixisenatide33$36,730
OzempicSemaglutide38$36,479
FarxigaDapagliflozin Propanediol25$35,304
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$9,718
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl55$5,741
ArexvyRsvpref3 Antigen/As01e/Pf12$3,731
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,097
Gabapentin133$1,645
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide98$981
Atorvastatin Calcium118$888
Albuterol Sulfate HfaAlbuterol Sulfate34$832
Levothyroxine Sodium79$760
Rosuvastatin Calcium97$752
Cefdinir42$719
Diclofenac Sodium40$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCSoliqua 100-33$35$36,73033 claims
Novo NordiskOzempic$140$36,47938 claims
AstraZenecaFarxiga$832$35,30425 claims
GSKArexvy$17$3,73112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →